cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.29456283.v1
title: Comparative efficacy of glioma treatment strategies: an umbrella review of meta-analyses

description: To assess the quality of evidence, identify potential biases, and verify the validity of existing studies on glioma treatment outcomes. We extracted and analyzed data from systematic reviews and meta-analyses assessing therapies in glioma patients. Our search included PubMed, Embase, Web of Science, and the Cochrane Database up to July 2024. Two authors independently evaluated each meta-analysis for methodological quality using the AMSTAR tool, following established evidence classification guidelines. This study evaluated 68 meta-analyses and 389 outcomes from 4,243 articles, classifying 193 outcomes as ‘very low’ quality, 96 as ‘low’ quality, 28 (7.2%) as ‘high’ quality, and 72 (18.5%) as ‘moderate’ quality, 156 as NS, 231 (59.4%) as Class IV, and 2 (0.005%) as Class III, respectively. High-quality evidence demonstrated that combining Traditional Chinese and Western medicine, adding bevacizumab (BVZ) to chemoradiotherapy (CRT), and other specific treatments improved overall survival (OS). Molecularly targeted drugs combined with temozolomide (TMZ) and radiotherapy (RT), as well as standard therapy augmented with anti-vascular endothelial growth factor or BVZ, prolonged progression-free survival (PFS). Additionally, treatments involving RT with TMZ or TMZ alone increased adverse events, whereas high-quality evidence showed that integrated Traditional Chinese and Western medicine, compared to Western medicine alone, reduced bone marrow suppression and gastrointestinal issues, enhancing treatment efficacy. High-quality evidence indicates that targeted therapy, immunotherapy, CRT, integrated Chinese and Western medicine, gene therapy, and combinations of targeted therapies with CRT or chemotherapy (CT) can extend OS and PFS in gliomas. However, CT, CRT, and targeted therapies, with or without additional CT or CRT, may increase adverse events. Integrated Chinese and Western medicine alone may reduce adverse effects.
DOI: 10.6084/m9.figshare.28264442
title: Identification of genetic variants of the <i>IL18R1</i> gene in association with COPD susceptibility

description: Although existing studies have identified some genetic loci associated with chronic obstructive pulmonary disease (COPD) susceptibility, many variants remain to be discovered. The aim of this study was to further explore the potential relationship between <i>IL18R1</i> single nucleotide polymorphisms (SNPs) and COPD risk. Nine hundred and ninety-six subjects were recruited (498 COPD cases and 498 healthy controls). Five candidate SNPs of <i>IL18R1</i> were selected and genotyped using MassARRAY iPLEX platform. Logistic regression analysis was performed to assess the association of these SNPs with COPD risk. Multifactor dimensionality reduction (MDR) software was applied to calculate the interaction of SNP-SNP on COPD risk. <i>IL18R1</i> rs9807989 (OR = 0.42, <i>p</i> &lt; .001), rs3771166 (OR = 0.40, <i>p</i> &lt; .001) and rs6543124 (OR = 0.44, <i>p</i> &lt; .001) were associated with the reduced COPD risk, while rs2287037 (OR = 2.71, <i>p</i> &lt; .001) and rs2058622 (OR = 2.06, <i>p</i> &lt; .001) might be the risk-increasing factor for COPD occurrence in both the overall analysis and subgroup analysis (age, gender, drinking, and smoking). The best multi-locus model was the combination of rs2058622 and rs3771166. Our study provided a reference and basis for investigating the association of <i>IL18R1</i> polymorphisms with COPD risk.
DOI: 10.6084/m9.figshare.28264442.v1
title: Identification of genetic variants of the <i>IL18R1</i> gene in association with COPD susceptibility

description: Although existing studies have identified some genetic loci associated with chronic obstructive pulmonary disease (COPD) susceptibility, many variants remain to be discovered. The aim of this study was to further explore the potential relationship between <i>IL18R1</i> single nucleotide polymorphisms (SNPs) and COPD risk. Nine hundred and ninety-six subjects were recruited (498 COPD cases and 498 healthy controls). Five candidate SNPs of <i>IL18R1</i> were selected and genotyped using MassARRAY iPLEX platform. Logistic regression analysis was performed to assess the association of these SNPs with COPD risk. Multifactor dimensionality reduction (MDR) software was applied to calculate the interaction of SNP-SNP on COPD risk. <i>IL18R1</i> rs9807989 (OR = 0.42, <i>p</i> &lt; .001), rs3771166 (OR = 0.40, <i>p</i> &lt; .001) and rs6543124 (OR = 0.44, <i>p</i> &lt; .001) were associated with the reduced COPD risk, while rs2287037 (OR = 2.71, <i>p</i> &lt; .001) and rs2058622 (OR = 2.06, <i>p</i> &lt; .001) might be the risk-increasing factor for COPD occurrence in both the overall analysis and subgroup analysis (age, gender, drinking, and smoking). The best multi-locus model was the combination of rs2058622 and rs3771166. Our study provided a reference and basis for investigating the association of <i>IL18R1</i> polymorphisms with COPD risk.
DOI: 10.6084/m9.figshare.29354426
title: Pain characteristics and psychological factors that mediate the association between obesity and outcomes of interdisciplinary pain rehabilitation: a registry-based cohort study

description: Obesity is a common comorbidity with chronic pain and is closely related to functional and psychological complications of pain, which are also the main outcomes of interdisciplinary pain rehabilitation programmes (IPRP). How obesity influences IPRP outcomes is poorly understood. This study aims to investigate the role of pain characteristics and psychological factors before IPRP as mediators of the association between obesity and IPRP outcomes (i.e. pain intensity and psychological functioning). Sociodemographic variables, pain characteristics and psychological factors were retrieved from the Swedish Quality Registry for Pain Rehabilitation (SQRP). Data at baseline (pre-IPRP) and 1-year follow-up (FU-IPRP) were used in mediation analysis. Of the 872 patients (mean age 45.8 ± 10.5 years, 80.3% female), 232 (26.6%) were obese (body mass index [BMI] ≥ 30 kg/m<sup>2</sup>). Patients with obesity reported higher pain intensity (<i>p</i> = 0.02), a higher number of pain locations (<i>p</i> &lt; 0.001), and longer pain duration (<i>p</i> = 0.002) compared to non-obese patients. Significant improvements at FU-IPRP were found in pain intensity and psychological functioning for both obese and non-obese groups. Mediation analysis revealed that pain intensity, pain radiation and depressive symptoms at pre-IPRP reduced the improvement of pain intensity at FU-IPRP among the patients with obesity. Depressive symptoms and pain intensity (or pain radiation) also mediated changes in two psychometric outcomes of IPRP (dysfunctional scale and adaptive coper scale). At FU-IPRP, patients with obesity experienced improvements in pain and psychological well-being, which were mediated by pain intensity, pain radiation, and depression. The roles of these mediators need to be specifically addressed when designing a tailored IPRP for pain patients with comorbid obesity. Patients with chronic pain and comorbid obesity had worse pain characteristics than non-obese peers before participating in a pain rehabilitation program.Pain intensity, pain radiation and depression mediated the improvements of rehabilitation for patients with chronic pain and comorbid obesity. Patients with chronic pain and comorbid obesity had worse pain characteristics than non-obese peers before participating in a pain rehabilitation program. Pain intensity, pain radiation and depression mediated the improvements of rehabilitation for patients with chronic pain and comorbid obesity.
DOI: 10.6084/m9.figshare.29354426.v1
title: Pain characteristics and psychological factors that mediate the association between obesity and outcomes of interdisciplinary pain rehabilitation: a registry-based cohort study

description: Obesity is a common comorbidity with chronic pain and is closely related to functional and psychological complications of pain, which are also the main outcomes of interdisciplinary pain rehabilitation programmes (IPRP). How obesity influences IPRP outcomes is poorly understood. This study aims to investigate the role of pain characteristics and psychological factors before IPRP as mediators of the association between obesity and IPRP outcomes (i.e. pain intensity and psychological functioning). Sociodemographic variables, pain characteristics and psychological factors were retrieved from the Swedish Quality Registry for Pain Rehabilitation (SQRP). Data at baseline (pre-IPRP) and 1-year follow-up (FU-IPRP) were used in mediation analysis. Of the 872 patients (mean age 45.8 ± 10.5 years, 80.3% female), 232 (26.6%) were obese (body mass index [BMI] ≥ 30 kg/m<sup>2</sup>). Patients with obesity reported higher pain intensity (<i>p</i> = 0.02), a higher number of pain locations (<i>p</i> &lt; 0.001), and longer pain duration (<i>p</i> = 0.002) compared to non-obese patients. Significant improvements at FU-IPRP were found in pain intensity and psychological functioning for both obese and non-obese groups. Mediation analysis revealed that pain intensity, pain radiation and depressive symptoms at pre-IPRP reduced the improvement of pain intensity at FU-IPRP among the patients with obesity. Depressive symptoms and pain intensity (or pain radiation) also mediated changes in two psychometric outcomes of IPRP (dysfunctional scale and adaptive coper scale). At FU-IPRP, patients with obesity experienced improvements in pain and psychological well-being, which were mediated by pain intensity, pain radiation, and depression. The roles of these mediators need to be specifically addressed when designing a tailored IPRP for pain patients with comorbid obesity. Patients with chronic pain and comorbid obesity had worse pain characteristics than non-obese peers before participating in a pain rehabilitation program.Pain intensity, pain radiation and depression mediated the improvements of rehabilitation for patients with chronic pain and comorbid obesity. Patients with chronic pain and comorbid obesity had worse pain characteristics than non-obese peers before participating in a pain rehabilitation program. Pain intensity, pain radiation and depression mediated the improvements of rehabilitation for patients with chronic pain and comorbid obesity.
DOI: 10.6084/m9.figshare.29446589
title: Exploring the perspectives of adolescent Ladies Gaelic Football players towards injury prevention: a qualitative study

description: In Ladies Gaelic football (LGF) there are 5.90 injury claims per 1000 adolescents per year. Injuries to adolescent players can negatively affect well-being, cause drop-out, and lead to the development of chronic conditions later in life. Evidence suggests injury prevention (IP) programmes designed for Gaelic games can reduce injury incidence, however, these programmes are not yet widely adopted. The aims of this study were to (1) determine the barriers and facilitators to IP strategy success in adolescent LGF and (2) identify adolescent LGF players’ preferences for IP strategies and educational interventions. Semi-structured interviews were conducted with 12 current adolescent LGF players (aged 14–17). The interviews were transcribed and reflexive thematic analysis was completed. This analysis involved gradually developing sub-themes, themes, and categories around the main concepts discussed in the interviews. Four players compete at both club and county level, and eight players compete at club level only. The main barriers to strategy success were negative stakeholder attitudes and issues with accessibility, knowledge, and unsuitable IP strategy characteristics. Players believed an appropriate IP strategy paired with promotional activities, support, strong leadership, improved education, and open communication would facilitate adoption. Players preferred an accessible, sport-specific IP programme containing flexibility, strength, and conditioning exercises. They felt this should be accompanied by guidance in several areas, particularly, load management, plus support from the governing body, clubs, and coaches. Players wanted IP education for players, coaches, and parents that focuses on injury prevention techniques, injury, and general health advice. They believed education would best be delivered in-person by educated coaches, players, or health and fitness professionals and supported by online resources. Reducing injury incidence and burden in the community sport of LGF is important. If the success of future IP strategies is to be maximized, the barriers and facilitators highlighted by adolescent players need to be addressed. Additionally, IP programmes and educational interventions designed to fit the preferences of stakeholders must be released and backed by governing bodies to support long-term adoption. Participating in organized sports such as Ladies Gaelic football is the leading cause of injury in adolescents, and the adoption rate of existing injury prevention programmes is low. To enhance injury prevention programme adoption, and ultimately reduce injury incidence in adolescent players, a new injury prevention strategy is required. This strategy should address negative attitudes, limited accessibility, and lack of education and establish programmes and educational interventions, which are reinforced by support, promotional activities, and strong leadership.
DOI: 10.6084/m9.figshare.29446589.v1
title: Exploring the perspectives of adolescent Ladies Gaelic Football players towards injury prevention: a qualitative study

description: In Ladies Gaelic football (LGF) there are 5.90 injury claims per 1000 adolescents per year. Injuries to adolescent players can negatively affect well-being, cause drop-out, and lead to the development of chronic conditions later in life. Evidence suggests injury prevention (IP) programmes designed for Gaelic games can reduce injury incidence, however, these programmes are not yet widely adopted. The aims of this study were to (1) determine the barriers and facilitators to IP strategy success in adolescent LGF and (2) identify adolescent LGF players’ preferences for IP strategies and educational interventions. Semi-structured interviews were conducted with 12 current adolescent LGF players (aged 14–17). The interviews were transcribed and reflexive thematic analysis was completed. This analysis involved gradually developing sub-themes, themes, and categories around the main concepts discussed in the interviews. Four players compete at both club and county level, and eight players compete at club level only. The main barriers to strategy success were negative stakeholder attitudes and issues with accessibility, knowledge, and unsuitable IP strategy characteristics. Players believed an appropriate IP strategy paired with promotional activities, support, strong leadership, improved education, and open communication would facilitate adoption. Players preferred an accessible, sport-specific IP programme containing flexibility, strength, and conditioning exercises. They felt this should be accompanied by guidance in several areas, particularly, load management, plus support from the governing body, clubs, and coaches. Players wanted IP education for players, coaches, and parents that focuses on injury prevention techniques, injury, and general health advice. They believed education would best be delivered in-person by educated coaches, players, or health and fitness professionals and supported by online resources. Reducing injury incidence and burden in the community sport of LGF is important. If the success of future IP strategies is to be maximized, the barriers and facilitators highlighted by adolescent players need to be addressed. Additionally, IP programmes and educational interventions designed to fit the preferences of stakeholders must be released and backed by governing bodies to support long-term adoption. Participating in organized sports such as Ladies Gaelic football is the leading cause of injury in adolescents, and the adoption rate of existing injury prevention programmes is low. To enhance injury prevention programme adoption, and ultimately reduce injury incidence in adolescent players, a new injury prevention strategy is required. This strategy should address negative attitudes, limited accessibility, and lack of education and establish programmes and educational interventions, which are reinforced by support, promotional activities, and strong leadership.
DOI: 10.6084/m9.figshare.29606884
title: Efficacy and safety of different acupuncture therapies in treating sleep apnea syndrome: a systematic review and network meta-analysis

description: To evaluate and rank the efficacy and safety of different acupuncture (AP) therapies in treating sleep apnea syndrome (SAS). We searched PubMed, Web of Science, Cochrane Library, Embase, Wanfang Data, CNKI, CBM, and VIP for randomized controlled trials (RCTs) studying AP for SAS until April 25, 2024. Effectiveness required a &gt;25% decrease in apnea-hypopnea index (AHI) and a &gt;1/3 reduction in symptom scores after treatment. Secondary outcomes included AHI, lowest oxygen saturation (LSaO₂), longest apnea time (LAT), Epworth Sleepiness Scale (ESS) score, and adverse events (AEs). We performed standard pairwise meta-analyses and network meta-analyses (NMA) using Stata15.1 and RStudio4.2.3, assessed evidence quality (GRADE), and ranked treatments using SUCRA values. Network meta-analysis of 43 randomized trials (3402 SAS patients) revealed distinct efficacy profiles: Electroacupuncture (EA) was the best intervention for reducing apnea-hypopnea index (AHI) (SUCRA=86.0%), while acupoint catgut embedding (ACE) ranked highest for both shortening longest apnea time (LAT) (SUCRA=98.7%) and improving lowest oxygen saturation (LSaO₂) (SUCRA = 89.7%). For reducing daytime sleepiness (ESS), manual acupuncture combined with Chinese herbal decoction (MA+OCHD) was most effective (SUCRA = 87.6%). In terms of overall clinical effectiveness rate, manual acupuncture plus Western medicine (MA+WM) performed best (SUCRA = 79.8%). Safety analysis showed Chinese herbal decoction (OCHD) alone was associated with the fewest adverse events (SUCRA = 93.4%). AP therapies are effective and safe for SAS. EA or ACE best improves breathing parameters, MA+OCHD best reduces sleepiness, and MA+WM yields the highest overall effectiveness. These findings guide SAS treatment selection.
DOI: 10.6084/m9.figshare.29606884.v1
title: Efficacy and safety of different acupuncture therapies in treating sleep apnea syndrome: a systematic review and network meta-analysis

description: To evaluate and rank the efficacy and safety of different acupuncture (AP) therapies in treating sleep apnea syndrome (SAS). We searched PubMed, Web of Science, Cochrane Library, Embase, Wanfang Data, CNKI, CBM, and VIP for randomized controlled trials (RCTs) studying AP for SAS until April 25, 2024. Effectiveness required a &gt;25% decrease in apnea-hypopnea index (AHI) and a &gt;1/3 reduction in symptom scores after treatment. Secondary outcomes included AHI, lowest oxygen saturation (LSaO₂), longest apnea time (LAT), Epworth Sleepiness Scale (ESS) score, and adverse events (AEs). We performed standard pairwise meta-analyses and network meta-analyses (NMA) using Stata15.1 and RStudio4.2.3, assessed evidence quality (GRADE), and ranked treatments using SUCRA values. Network meta-analysis of 43 randomized trials (3402 SAS patients) revealed distinct efficacy profiles: Electroacupuncture (EA) was the best intervention for reducing apnea-hypopnea index (AHI) (SUCRA=86.0%), while acupoint catgut embedding (ACE) ranked highest for both shortening longest apnea time (LAT) (SUCRA=98.7%) and improving lowest oxygen saturation (LSaO₂) (SUCRA = 89.7%). For reducing daytime sleepiness (ESS), manual acupuncture combined with Chinese herbal decoction (MA+OCHD) was most effective (SUCRA = 87.6%). In terms of overall clinical effectiveness rate, manual acupuncture plus Western medicine (MA+WM) performed best (SUCRA = 79.8%). Safety analysis showed Chinese herbal decoction (OCHD) alone was associated with the fewest adverse events (SUCRA = 93.4%). AP therapies are effective and safe for SAS. EA or ACE best improves breathing parameters, MA+OCHD best reduces sleepiness, and MA+WM yields the highest overall effectiveness. These findings guide SAS treatment selection.
DOI: 10.6084/m9.figshare.30552965
title: Molecular features influencing clinical outcome of advanced HER2-positive gastric cancer receiving trastuzumab plus chemotherapy

description: Less than half of the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) patients respond to trastuzumab plus chemotherapy, and the outcomes are unsatisfactory. Understanding the underlying mechanisms remains crucial for identifying patients who are more likely to benefit from treatment. We performed targeted DNA sequencing on paired pre-treatment and progressive tumour tissues from 22 HER2-positive advanced GC patients undergoing first-line treatment with trastuzumab and chemotherapy. Clinicopathological and genomic characteristics were assessed for the correlation with clinical outcomes. A performance status (PS) of 0–1 was associated with improved progression-free survival (PFS) and overall survival (OS) than a PS of 2. Poorly differentiated tumours exhibited shorter PFS than moderate or moderate-poor ones. Pre-treatment amplification of <i>MYC</i> or <i>TOP2A</i> gene was association with increased PFS, and suggested a potential benefit for OS. Patients with higher tumour mutation burden (TMB) experienced significantly worse PFS, while higher chromosome instability (CIN) appeared to be correlated with longer PFS. Compared to non-responders, responders had a higher CIN but similar TMB and intratumoural heterogeneity (ITH). PS and <i>MYC</i> amplification emerged as independent factors related to PFS according to multivariate survival analysis. Additionally, after treatment, TMB significantly increased in non-responders, while CIN significantly decreased in responders. Pre-treatment <i>MYC</i> amplification and PS were independently associated with clinical outcomes in HER2-positive advanced GC patients treated with first-line trastuzumab plus chemotherapy. Dynamic post-treatment changes in TMB and CIS provide valuable insights into the relationship between therapeutic response and distinct evolutionary trajectories.